Prognostic Value of SPARC Expression in Unresectable NSCLC Treated with Concurrent Chemoradiotherapy

Kurtul, Neslihan; Eroglu, Celalettin; Unal, Dilek; Tasdemir, Erdem Arzu; Orhan, Okan; Zararsiz, Gokmen; Baran, Munevver; Kaplan, Bunyamin; Kontas, Olgun

추천

검색

자료유형: 학술저널

저자정보: Kurtul, Neslihan (Department of Radiation Oncology, Sutcu Imam University Medical Faculty) Eroglu, Celalettin (Department of Radiation Oncology, Erciyes University Medical Faculty) Unal, Dilek (Department of Radiation Oncology, Kayseri Education and Research Hospital) Tasdemir, Erdem Arzu (Department of Pathology, Kayseri Education and Research Hospital) Orhan, Okan (Department of Radiation Oncology, Erciyes University Medical Faculty) Zararsiz, Gokmen (Department of Biostatistics and Medical Informatics, Erciyes University Medical Faculty) Baran, Munevver (Department of Pathology, Erciyes University Medical Faculty) Kaplan, Bunyamin (Department of Radiation Oncology, Erciyes University Medical Faculty) Kontas, Olgun (Department of Pathology, Erciyes University Medical Faculty)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제20호

발행연도: 2014.1

수록면: 8,911 - 8,916 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The aim of the present study was to determine the predictive/prognostic value of the secreted protein, acidic and rich in cysteine (SPARC) in cases of unresectable, locally advanced, non-small cell lung cancer. Materials and Methods: The study included 84 patients with Stage IIIA-B non-small cell lung cancer, undergoing simultaneous chemoradiotherapy including radiotherapy at a dose of 66 Gy and weekly docataxel ($20mg/m^2$) and cisplatin ($20mg/m^2$). SPARC expression was studied in biopsy material by immunohistochemical methods and correlations with treatment responses or survival were evaluated. Results: Median overall survival was $16{\pm}2.73$ (11.55-20.46) months for low expression vs $7{\pm}1.79$ months (7.92-16.08) months for high expression (p=0.039), while median local control was $13{\pm}2.31$ (8.48-17.5) months for low expression vs $6{\pm}0.85$ (4.34-7.66) months for high expression (p=0.045) and median progression-free survival was $10{\pm}2.31$ (5.48-14.5) months for low expression vs $6{\pm}1.10$ (3.85-8.15) months for high expression (p=0.022). In both univariate and multivariate analyses, high SPARC expression was associated with significantly shorter overall survival (p=0.003, p=0.007, respectively), local control (p=0.008, p=0.036) and progression-free survival (p=0.004, p=0.029) when compared to low SPARC expression. No significant difference was detected between high and low SPARC expression groups regarding age, sex, T stage, N stage, histopathology and stage-related patient characteristics. Conclusions: High SPARC expression was identified as a poor prognostic factor in cases with locally advanced NSCLC treated with concurrent chemoradiotherapy.

#NSCLC #SPARC expression #prognosis #chemoradiotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요